An Open Label, Multicenter, Phase II Study of Belantamab Mafodotin in Combination With VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
Latest Information Update: 17 Jan 2023
At a glance
- Drugs Belantamab mafodotin (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 13 Dec 2022 Initial safety and efficacy results (n=40, as of data cut off date of July 7th 2022) of patients included after 4 cycles of induction with Belamaf-VRd presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 29 Mar 2021 Status changed from not yet recruiting to recruiting.
- 22 Mar 2021 New trial record